Streetbeat News

Regulatory

HUGE

FSD Pharma announced the submission of a clinical trial application for a Phase-1b trial, METAL-1, to assess the safety and efficacy of Unbuzzd in healthy volunteers under alcohol intoxication. The application has been submitted for ethics review in Australia, with volunteer recruitment expected to start in April pending approval.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:07 pm

NRIX

Nurix Therapeutics' stock price increased following the announcement that the FDA has lifted the partial clinical hold on its NX-2127 Phase 1 trial. This development allows the company to proceed with the trial, potentially advancing its research and development efforts in the pharmaceutical sector.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:01 pm

CGC

Canopy Growth Corporation (CGC) announced a special resolution for shareholders to vote on creating an unlimited number of new non-voting, non-participating exchangeable shares. This amendment also includes a conversion feature allowing common shares to be converted into exchangeable shares and vice versa. The vote is scheduled for April 12, 2024. If approved, this will enable shareholders to convert their shares post the effective time of the amendment. Notices of Conversion will be available on the company's website and filed with the SEC and Canadian regulators.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:59 am

NLSP

NLS Pharmaceutics has received approval from the Nasdaq Listing Qualifications Department for its compliance plan submitted on February 23, 2024. This approval is a crucial step for the company in maintaining its listing on the Nasdaq stock market.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:38 am

AUVI

Applied UV, through its SteriLumen subsidiary, has filed a patent application for a 'Disinfection System Comprised of Multiple Wavelengths Each Controlled Optimally'. This innovation could potentially enhance the effectiveness of disinfection systems by utilizing a combination of wavelengths, each optimized for specific disinfection purposes.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:33 am

USPH

U.S. Physical Therapy announced a change in the Medicare rate reduction for the remainder of 2024. The new rate reduction effective March 9, 2024, will be approximately 1.8%, a decrease from the previously expected 3.5%. This change is not retroactive to January 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:24 am

COIN

HOOD

QQQ

SPY

U.S. stocks are poised for a lower open as investors await the February CPI report, crucial for the Fed's rate decision. Last week, major indices closed lower, with tech stocks leading the decline. Analysts remain optimistic about the 'Magnificent 7' stocks despite recent volatility. SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw premarket declines. Coinbase and Robinhood surged with Bitcoin's rise. Asana, Casey's General Stores, Oracle, and Vail Resorts are set to report earnings. Global markets showed mixed reactions, with Asian markets mostly down and European markets opening lower.

Portfolio Pulse from Shanthi Rexaline

March 11, 2024 | 11:24 am

LXRX

Lexicon Pharmaceuticals' shares surged after the company announced plans to resubmit its Sotagliflozin NDA for Type 1 diabetes based on FDA feedback. Furthermore, Lexicon revealed a securities purchase agreement anticipated to generate approximately $250 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:22 am

PMN

ProMIS Neurosciences has received patent approvals from the European Patent Office, Japanese Patent Office, and IP Australia for PMN310, a novel monoclonal antibody for Alzheimer's disease treatment. These patents cover the composition of matter and method of use for PMN310, which targets toxic oligomers of amyloid-beta, a key factor in Alzheimer's disease progression.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:19 am

TVTX

Travere Therapeutics has submitted a Supplemental New Drug Application (sNDA) to the FDA for full approval of FILSPARI, aimed at treating IgA Nephropathy. This step could mark a significant advancement in the treatment options available for this kidney disease.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:12 am